Adicet Bio (LTS:0HX7) Total Liabilities: $29.32 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
31 GF Score
Price $8.66
GF Value $0.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Total Liabilities?

Adicet Bio LTS:0HX7 +0.12% 31 Total Liabilities is $29.32 Mil as of Mar. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 31/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Adicet Bio's Total Liabilities for the quarter that ended in Mar. 2026 was $29.32 Mil.

Adicet Bio's quarterly Total Liabilities increased from Sep. 2025 ($31.34 Mil) to Dec. 2025 ($33.15 Mil) but then declined from Dec. 2025 ($33.15 Mil) to Mar. 2026 ($29.32 Mil).

Adicet Bio's annual Total Liabilities declined from Dec. 2023 ($37.12 Mil) to Dec. 2024 ($33.61 Mil) and declined from Dec. 2024 ($33.61 Mil) to Dec. 2025 ($33.15 Mil).

Adicet Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Total Liabilities Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 35.81 38.35 37.12 33.61 33.15

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.83 29.60 31.34 33.15 29.32
LTS:0HX7
31GF Score
Adicet Bio Inc LTS:0HX7
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adicet Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.531+(11.552+0.062000000000005
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=33.15

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=192.355-159.21
=33.15

Adicet Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.298+(11.019+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=29.32

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=169.382-140.065
=29.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $29.32 Mil mean?
Adicet Bio (LTS:0HX7) has a Total Liabilities of $29.32 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adicet Bio and its competitors.
Is Adicet Bio's Total Liabilities too high?
Adicet Bio's current Total Liabilities is $29.32 Mil. Overall, Adicet Bio has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Total Liabilities compare to ATRA and PYPD?
Adicet Bio's Total Liabilities of $29.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adicet Bio and its competitors. Adicet Bio's current Total Liabilities is $29.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $8.66 — trading 1868.2% above its estimated fair value. The current Total Liabilities is $29.32 Mil. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Total Liabilities is $29.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adicet Bio (LTS:0HX7) Overvalued in 2026?

Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued. The current stock price of $8.66 is trading 1868.2% above its estimated GF Value™ of $0.44. GuruFocus considers Adicet Bio to be Significantly Overvalued.

Key valuation signals for LTS:0HX7:

  • Total Liabilities: $29.32 Mil
  • GF Value™: $0.44 vs. price of $8.66 (1868.2% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for LTS:0HX7

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.66
Price
$0.44
GF Value